The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

Introduction Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a considerable impact on patients’ quality of life and healthcare budgets. Biosimilar infliximab (Remsima ® ) has been authorized...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2015-08, Vol.32 (8), p.742-756
Hauptverfasser:	Jha, Ashok, Upton, Alex, Dunlop, William C. N., Akehurst, Ron
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - economics Antirheumatic Agents - therapeutic use Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - economics Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - economics Biosimilar Pharmaceuticals - economics Biosimilar Pharmaceuticals - therapeutic use Cardiology Cost Savings - methods Cost Savings - statistics & numerical data Drug Costs - statistics & numerical data Endocrinology Europe Female Health technology assessment Humans Infliximab - economics Infliximab - therapeutic use Internal Medicine Male Medicine Medicine & Public Health Models, Econometric Oncology Original Research Pharmacology/Toxicology Prescription Fees - statistics & numerical data Rheumatology Spondylitis, Ankylosing - drug therapy Spondylitis, Ankylosing - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!